YD Bio (Nasdaq: YDES) announced full-year 2025 financial results showing 17% net revenue increase to $596.8 million, driven by pharmaceutical sales growth and new product launches. However, the company reported a net loss of $8.3 million compared to $1.4 million in 2024, primarily due to a $3.2 million change in warrant liabilities and increased operating expenses from business expansion. The company ended 2025 with $6.0 million in cash and outlined 2026 strategic priorities including FDA submissions for its Limbal Stem Cell platform and pancreatic cancer detection program, along with planned M&A activities.
Mixed financial performance with positive revenue growth (17% increase) and successful business combination, but offset by significant net loss expansion ($8.3M vs $1.4M), declining gross margins due to product mix shift, and substantial warrant liability charges. While management commentary shows optimistic forward guidance with multiple clinical milestones planned for 2026, the deteriorating profitability and low cash position ($6.0M) present near-term operational concerns.